HR Execs on the Move

Aphria Incorporated

www.aphriainc.com

 
Headquartered in Leamington, Ontario – the greenhouse capital of Canada – Aphria has been setting the standard for safe, clean and pure pharmaceutical-grade cannabis at scale, grown in the most natural conditions possible.
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.aphriainc.com
  • PO Box 20009 269 Erie St South
    Leamington, ON CAN N8H 3C4
  • Phone: 844.427.4742

Executives

Name Title Contact Details
Maureen Berry
Vice President of Corporate Human Resources Profile

Similar Companies

Cirrus Pharmaceuticals

Cirrus Pharmaceuticals is a Durham, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Nexelis, a Q² Solutions

On the Forefront of COVID-19 Recognized leader in the COVID-19 field by governmental and non-governmental organizations as the reference assay...

OVP HEALTH

HEALTHIER. COMMUNITY. OVP HEALTH provides an extensive range of addiction treatment services, emergency department and hospitalist staffing and management services.

IriSys Inc

IriSys Inc is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Zentaris

Aeterna Zentaris Inc. is a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests. The Company`s lead product, Macrilen™ (macimorelin), is the first and only U.S. FDA and European Commission approved oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). Macrilen™ is currently marketed in the United States through a license agreement with Novo Nordisk and Aeterna Zentaris receives double-digit royalties on sales. Aeterna Zentaris owns all rights to macimorelin outside of the U.S. and Canada. Aeterna Zentaris is also leveraging the clinical success and compelling safety profile of macimorelin to develop it for the diagnosis of child-onset growth hormone deficiency (CGHD), an area of significant unmet need. The Company is actively pursuing business development opportunities for the commercialization of macimorelin in Europe and the rest of the world, in addition to other non-strategic assets to monetize their value.